PPARA and metabolic dysfunction-associated steatohepatitis: Together with the anti-inflammatory function of pan PPAR-iMSC-EVs in NASH mice [34] as well as cisplatin-mediated AKI in the present study, these findings support that pan PPAR agonists may affect specific pathways in iMSCs, yielding distinct cargo biomolecules to reduce inflammation.